Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b/2a basket trial to assess safety and efficacy of IDX-1197 in
patients with HRR mutation.
There are two parts to this study: Phase 1b, IDX-1197 dose-selection study to determine RP2D
and Phase 2a, non-randomized parallel dose expansion study to confirm RP2D.